Lexicon Pharmaceuticals | LXRX - Assets


Lexicon Pharmaceuticals reported $268.82M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Illumina USD 6.65B 91M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
J&J USD 197.42B 3.64B Sep/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
MannKind USD 732.3M 12.1M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Moderna USD 10.96B 527M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025